Biogen Drug Shows Promise in Phase 2 Cutaneous Lupus Trial
Litifilimab achieved clear or almost clear skin in 14.7% of patients at Week 16 versus 2.9% on placebo in...
Brepocitinib VALOR Trial Shows Positive Dermatomyositis Data
In the Phase 3 VALOR trial (n=241), brepocitinib 30 mg once-daily delivered a 15.3-point greater improvement in mean Total...
MoonLake Reveals New Sonelokimab HS Phase 3 Trial Results
At Week 40 in the Phase 3 VELA program for moderate-to-severe hidradenitis suppurativa (HS), sonelokimab achieved a 62% HiSCR75...
Spectral & Vantive Publish Tigris Trial Results in Lancet
In the Phase 3 Tigris trial of 157 adults with endotoxic septic shock, polymyxin B hemoadsorption (PMX) achieved a...
Minerva Presents Safety Trial Data on Roluperidone, Olanzapine
Minerva Neurosciences reported that an open-label safety study of roluperidone coadministered with olanzapine showed no clinically significant adverse effects...
LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial
Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by...
BEAM-302 Trial Shows Compelling Data for AATD Treatment
Beam’s Phase 1/2 readout for BEAM-302 in severe alpha-1 antitrypsin deficiency (AATD) delivered clean, quantitative signals: at the 60...
C4 Therapeutics Begins Phase 1b Trial for Multiple Myeloma
C4 Therapeutics has dosed the first patient in a Phase 1b study assessing cemsidomide plus dexamethasone in combination with...
Aclaris Announces Phase 2a Trial Results for ATI-2138 at AAD
Aclaris will present new results from its open-label Phase 2a study of ATI-2138, an oral covalent inhibitor of ITK...
Wallaby Treats First U.S. Patient in PIANO Aneurysm Trial
More than 20,000 patients have been treated outside the United States with the p48 and p64 MW HPC flow...